Keywords
How to Cite
Abstract
Acute Lymphoblastic Leukemia (ALL) in children is a challenging condition that requires a complex and multidisciplinary therapeutic approach. In the pediatric treatment of ALL, continuous monitoring plays a crucial role in assessing treatment response and adjusting strategies as needed. The use of imaging methods, such as magnetic resonance imaging and computed tomography, along with specialized laboratory tests, allows for a more precise analysis of the disease's progression and its effects on the pediatric organism.
Frequent patient follow-up is essential to identify potential complications and side effects associated with therapies, enabling early intervention when necessary. Furthermore, the assessment of the emotional and psychological state of children and their families plays a significant role in the holistic treatment of ALL. The patient-centered approach not only considers the effectiveness of medical interventions but also aims to promote the emotional and social well-being of those involved, assisting in the adaptation to this challenging journey.
In the realm of future perspectives in pediatric ALL treatment, advances in genomic research and targeted therapies offer significant promises. Personalizing treatment protocols based on the specific genetic characteristics of each patient has the potential to enhance efficacy and reduce adverse effects. Additionally, innovative immunotherapies, such as CAR-T therapy, are being explored as promising alternatives, showing encouraging results in clinical studies. These innovative approaches represent a new era in pediatric ALL treatment, bringing hope for substantial improvements in the quality of life and cure rates for affected children.
In summary, the approach to Acute Lymphoblastic Leukemia treatment in Pediatrics requires continuous vigilance, utilizing advanced monitoring tools to adapt therapeutic strategies as the disease evolves. Additionally, consideration of the patient's and their family's emotional and social well-being is fundamental. Future prospects are promising, with advancements in genomics, targeted therapies, and innovative immunotherapies paving the way for more effective and personalized treatment.
References
ALMAEEN, Abdulrahman H. et al. CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects. Biomedicines, v. 11, p. 2693, 2023.
ANSARI, Faezeh et al. A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Leukemia Research, v. 135, p. 107416, 2023.
DUFRAYER, Mauro Cesar et al. Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil. Brazilian Journal of Infectious Diseases, v. 27, n. 2, p. 102745, 2023.
HEFAZI, Mehrdad; LITZOW, Mark R. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, v. 13, p. 265–274, 2018.
HIRAMATSU, Hidefumi. Current status of CAR‑T cell therapy for pediatric hematologic malignancies. International Journal of Clinical Oncology, v. 28, p. 729–735, 2023.
HUANG, Yuan-hong et al. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of Hematology, v. 102, p. 2001–2013, 2023.
HUNGER, Stephen P et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematology, v. 10, p. e510–20, 2023.
IVANOV, Anca Viorica et al. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies—From Pathway to Target. International Journal of Molecular Sciences, v. 24, p. 4661, 2023.
JÉHA, Sima. Relapsed/Refractory T‑ Acute Lymphoblastic Leukemia — Current Options and Future Directions. Indian Journal of Pediatrics, 2023.
MILLER, Lane H. et al. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions. Expert Review of Anticancer Therapy, 2023.
QIU, Kun-yin et al. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial. American Journal of Hematology, ;98:869–880, 2023.
VAN DER SLUIS, Inge M. et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. New England Journal of Medicine; 388:1572-81, 2023.
TEMPLE, William C. et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents, and young adults. Best Practice & Research Clinical Haematology, v. 36, p. 101449, 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Pâmela Camila dos Santos Ramos , Yasmin Suassuna Lacerda de Vasconcelos, Lizanka Dias Abrantes , Desirée Duarte Serra , Luciane Mari Brito Cavalcante